<?xml version="1.0" encoding="UTF-8" standalone="no"?>
<ibecs-document>
<record>
<header>
<identifier>ibc-045131</identifier>
<setSpec>1130-6343</setSpec>
</header>
<metadata xmlns="http://example.org/myapp/" xmlns:dc="http://purl.org/dc/elements/1.1/" xmlns:dcterms="http://purl.org/dc/terms/" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" xsi:schemaLocation="http://example.org/myapp/schema.xsd">
<dc:title xml:lang="en">A study of initial antiretroviral therapy effectiveness, survival and safety in HIV+ patients</dc:title>
<dc:description xml:lang="en">Objective: To study initial antiretroviral therapies indicatedfor HIV-infected patients during the 2001-2003 period regardingeffectiveness, survival and safety.Method: A descriptive, retrospective study of clinical anddrug-related variables of naïve HIV-infected patients throughpharmacotherapeutic history.Results: Mean CD4+ lymphocytes counts were 209.6cells/mm3. Pneumonia by Pneumocystis carinii was the mostcommonly found condition at antiretroviral treatment onset. Mostcommonly used therapies included those based on a non-nucleosidereverse transcriptase inhibitor (NNRTI) combined with twonucleoside reverse transcriptase inhibitors (NRTIs). The longestmean survival was achieved by using combinations of three nucleosidereverse transcriptase inhibitors. The primary reason for initialantiretroviral therapy discontinuation were adverse effects,with stavudine exhibiting the poorest tolerability.Conclusions: Therapies based on non-nucleoside reversetranscriptase inhibitors and protease inhibitors (PIs) have shownsimilar effectiveness to increase CD4+ cell counts. Regarding viralload decreases, protease inhibitors were most effective. Therapiesusing three nucleoside reverse transcriptase inhibitors resulted inpeak survival</dc:description>
<dc:creator>Rabaneque Hernández, M. J</dc:creator>
<dc:creator>Allende-Bandrés, M. A</dc:creator>
<dc:creator>Mendaza Beltrán, M</dc:creator>
<dc:creator>Arenere Mendoza, M</dc:creator>
<dc:creator>cilveti-Sáchez, U</dc:creator>
<dc:creator>Navarro Aznárez, H</dc:creator>
<dc:language>es</dc:language>
<dc:description xml:lang="es">Objetivo: Estudiar los tratamientos antirretrovirales de inicioindicados en pacientes VIH durante el periodo 2001-2003, suefectividad, supervivencia y seguridad.Método: Estudio descriptivo retrospectivo de las variables clínicasy farmacológicas de los pacientes VIH naïve a través de lahistoria farmacoterapéutica.Resultados: La media de linfocitos CD4+ ha sido 209,6 células/mm3. La neumonía por Pneumocystis carinii ha sido la principalenfermedad presente al iniciar tratamiento antirretroviral.Las terapias más utilizadas han sido las basadas en la utilización deun inhibidor de la transcriptasa inversa no análogo de los nucleósidos(ITINN) combinado con dos inhibidores análogos (ITIAN). Lascombinaciones de tres inhibidores de la transcriptasa inversa análogosde los nucleósidos presentaron la mayor supervivenciamedia. El principal motivo de suspensión de terapia inicial hansido los efectos adversos, siendo la estavudina el peor tolerado.Conclusiones: Las terapias basadas en inhibidores de la transcriptasainversa no análogos de los nucleósidos e inhibidores de laproteasa (IPs) han demostrado una efectividad similar en el incrementode células CD4+. En la disminución de los niveles de cargaviral los inhibidores de la proteasa han resultado más efectivos. Lasterapias con tres inhibidores de la transcriptasa inversa análogos delos nucleósidos han presentado la mayor supervivencia</dc:description>
<dc:source>Farm Hosp;29(5): 323-330, sep.-oct. 2005. tab, graf</dc:source>
<dc:identifier>ibc-045131</dc:identifier>
<dc:title xml:lang="es">Estudio de la efectividad, supervivencia y seguridad de las terapias antirretrovirales de inicio en pacientes VIH+</dc:title>
<dc:subject>^d29611</dc:subject>
<dc:subject>^d24718^s22057</dc:subject>
<dc:subject>^d21034</dc:subject>
<dc:subject>^d29770</dc:subject>
<dc:subject>^d21030</dc:subject>
<dc:subject>^d21044</dc:subject>
<dc:subject>^d32626^s22079</dc:subject>
<dc:subject>^d11924^s22079</dc:subject>
<dc:subject>^d33123^s22083</dc:subject>
<dc:subject>^d16735</dc:subject>
<dc:subject>^d38332^s22073</dc:subject>
<dc:subject>^d35395^s22083</dc:subject>
<dc:subject>^d24525^s22021</dc:subject>
<dc:type>article</dc:type>
<dc:date>200510</dc:date>
</metadata>
</record>
</ibecs-document>
